Difference between revisions of "Sexy Librarian Strikes Again!"

Drug Companies Vie For "Life Enhancement" Patent

Los Angeles, CA - September 23, 2008 - Verdus Pharmaceuticals, a top US drug corporation, has filed suit against LifesBlood LLC, a former "experimental" sub-division of its Research and Development department. LifesBlood recently severed ties to its parent company to form its own initiative. But Verdus claims LBL has stolen several projects in its departure, and is now suing the start-up for not only copyright infringement, but corporate espionage. One patent in particular, an as yes untitled "lifestyle enhancement medication," seems to be the main issue of contention.

Verdus CEO Ted McKinley claims "what [LBL] has done is unconscionable. We were developing a treatment that could radically change the health industry for the betterment of mankind, and all they see are dollar signs." McKinly (sic) goes on to say, "at first, [ours] was a mutual partnership. A successful one at that. But if Dr. Alderman and his colleagues feel the need to attain sole credit for this breakthrough, we at Verdus simply cannot let that pass."

McKinley is referring to Dr. Leonard Alderman, CEO and Founder of LifesBlood, LLC. Alderman anointed himself Director of Medical Research for the new LifesBlood Labs initiative, and has already promised several breakthroughs in the fields of phlebotomy and regenerative medicine. While still in the process of patent and FDA approval, Alderman guarantees that what they've created will be available for public consumption in the near future. "It would be wrong of us to keep these amazing things from those who need them most. We hope to roll out the technologies before the end of 2009."

But McKinley believes Harrison's motives have more to do with advancing profit margins for LBL: "It's simply a transparent effort to appeal to potential investors."

Alderman, however, sees things a little differently: "Our relationship with Verdus has been quite fruitful over the years, but it became clear that our goals had rapidly diverged. We wish Verdus and its various affiliations nothing but continued success." Harrison later added: "If Ted can't fit his head through the door anymore, that's his problem. Not ours."

McKinley was recently promoted from VP of Biotherapeutics at Verdus to CEO when the company's former chief executive officer, Elizabeth Avery, retired several months ago. He chose not to respond to Alderman's additional statement.

Verdus's suit demands records of all correspondence, email, and other communications between Harrison and his staff. Verdus also asks the court to order LBL to immediately process the documents for release.

An initial trial date is expected to be set for early Spring of 2009.